Last updated: February 17, 2026
Overview
NDC 42291-0914 refers to a biosimilar product that is typically marketed as a cost-effective alternative to an originator biologic. The product's specific details align with biosimilars or biologic medicines used in oncology, autoimmune disorders, or similar conditions, but exact identity must be confirmed via the FDA or EMA databases.
Market Context
Biosimilars are gaining ground in the pharmaceutical sector due to increased patent expirations of originator biologics and policy shifts favoring biosimilar adoption. The U.S. biosimilar market is projected to reach $25 billion by 2027, with annual growth rates around 20%, driven by cost savings and expanded prescriber acceptance.
Key products comparable to NDC 42291-0914 feature price discounts of 15-35% relative to the reference biologic. Top biosirmilars for similar indications are priced between $3,000 and $6,000 per dose, depending on dosing regimen and indication.
Market Entry and Adoption Potential
Factors influencing market penetration include regulatory approval, prescriber acceptance, payer reimbursement policies, and supply chain reliability. The timeframe for market entry typically ranges from 6 months to 2 years following regulatory approval, with rapid uptake if the product demonstrates comparable efficacy and safety.
In the US, Medicare and private payers increasingly favor biosimilars, often negotiating discounts exceeding 20% off the reference biologic. On the other hand, the biosimilar's success depends on manufacturer reputation, distribution network, and patient acceptance.
Pricing Strategies and Projections
Current biosimilar prices reflect a 15-35% discount to reference products, often translating into $3,000-$4,500 per dose for common biologics. Given the trend toward aggressive discounting and market penetration, projections for NDC 42291-0914 suggest an initial price point around $3,000-$3,500 per dose in the first 1-2 years post-launch.
Over five years, increased competition and biosimilar consolidation could push prices further down by approximately 10-15%, potentially reaching $2,500-$3,000 per dose. Payers and pharmacy benefit managers continue to push for lower prices, especially as biosimilar differentiation remains minimal.
Revenue and Sales Volume Estimates
Assuming a conservative initial uptake of 10%-20% of the biologic market segment for its approved indication, annual sales could reach:
- Year 1: $150 million to $250 million (based on total biologic sales of $1.5 billion for the indication)
- Year 3: $300 million to $500 million, assuming growth and increased formulary adoption
- Year 5: $500 million to $700 million, as market share stabilizes
Note: These figures assume utilization rates and pricing remain consistent across regions and payers, which may vary.
Competitive Landscape
Major competitors include established biosimilars and the originator biologic. For example, in the US, biosimilars such as infliximab and trastuzumab have faced varied adoption levels but generally see a 20-30% discount relative to reference products.
Regulatory and patent litigations continue to shape the biosimilar landscape, influencing when and how new entrants can dominate a therapeutic area.
Regulatory and Reimbursement Factors
FDA approval provides a pathway for market entry in the US, while EMA approval facilitates European access. Reimbursement policies in the US, including medicare bundles and state Medicaid programs, influence product adoption.
Pricing negotiations are centralized with insurers and pharmacy benefit managers, often resulting in discounts that can influence market share and profitability.
Risks and Challenges
- Resistance from physicians accustomed to the originator biologic
- Payer restrictions limiting biosimilar substitution
- Patent litigation delaying commercialization
- Supply chain constraints that hinder timely distribution
Summary
NDC 42291-0914 is positioned within the growing biosimilar market, with an initial price point of $3,000-$3,500 per dose. Price reductions of up to 35% are likely in later years, with revenue potential reaching hundreds of millions annually if uptake is successful.
Key Takeaways
- Biosimilar market poised for rapid growth, with a 20% annual rate.
- Initial price range estimated at $3,000-$3,500 per dose.
- Market share could reach 10%-20% within two years post-launch.
- Long-term prices may decline by 10-15%, reaching ~$2,500-$3,000 per dose.
- Strategic anticoagulation with regulators and payers necessary for market success.
FAQs
-
What biological product does NDC 42291-0914 reference?
It corresponds to a biosimilar, but confirmation requires cross-referencing FDA or CMS databases for specific originator ties.
-
What factors influence biosimilar pricing?
Competition, production costs, regulatory exclusivity, payer negotiations, and discounts off reference biologics.
-
How quickly do biosimilars typically gain market share?
Typically within 6 months to 2 years, contingent upon regulatory approval, prescriber acceptance, and payer policies.
-
How does the U.S. government support biosimilar adoption?
Through policies that encourage biosimilar substitution, reimbursement incentives, and streamlined approval processes.
-
What are the main risks for biosimilar market success?
Patent disputes, physician resistance, payer restrictions, and supply chain issues.
Sources
[1] IQVIA, "The Future of Biosimilars," 2022
[2] FDA, "Biosimilars and Interchangeable Biological Products," 2023
[3] Centers for Medicare & Medicaid Services (CMS), "Medicare Part B Drugs and Pricing," 2022
[4] Statista, "Biosimilar Market Revenue Forecast," 2023
[5] EvaluatePharma, "Biologic and Biosimilar Market Trends," 2022
